{"transactions":[{"id":4626561,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626560,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626559,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626558,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626557,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626556,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626555,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":30.14,"expiration_date":"2030-04-27","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626554,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":23.85,"expiration_date":"2029-04-29","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626553,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":24.43,"expiration_date":"2028-04-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626552,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":4626551,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:32:38.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":91204,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001199297-26-000006","document":"form4-09252026_120934.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000119929726000006/form4-09252026_120934.xml","form_type":"4"}},{"id":735984,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:37:40.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001199297-26-000003","document":"form4-06172026_010636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000119929726000003/form4-06172026_010636.xml","form_type":"4"}},{"id":735983,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:37:40.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":97213,"source":{"system":"sec-edgar","filing":"0001199297-26-000003","document":"form4-06172026_010636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000119929726000003/form4-06172026_010636.xml","form_type":"4"}},{"id":739832,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:23:57.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":648,"derivative":{"exercise_price":240.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":648},"source":{"system":"sec-edgar","filing":"0001689548-26-000059","document":"wk-form4_1781299435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000059/wk-form4_1781299435.xml","form_type":"4"}},{"id":739831,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:23:57.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":1371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":18622,"source":{"system":"sec-edgar","filing":"0001689548-26-000059","document":"wk-form4_1781299435.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000059/wk-form4_1781299435.xml","form_type":"4"}},{"id":1032328,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-25T20:40:48.000Z","date":"2025-09-24","kind":"exercise","planned":false,"acquired":false,"shares":1753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025."}],"balance_after":8767,"derivative":{"exercise_price":44.04,"expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":1753},"source":{"system":"sec-edgar","filing":"0001689548-25-000096","document":"wk-form4_1758832845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000096/wk-form4_1758832845.xml","form_type":"4"}},{"id":1032327,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-25T20:40:48.000Z","date":"2025-09-24","kind":"exercise","planned":false,"acquired":false,"shares":8566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was fully vested as of June 5, 2025."}],"balance_after":0,"derivative":{"exercise_price":44.25,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":8566},"source":{"system":"sec-edgar","filing":"0001689548-25-000096","document":"wk-form4_1758832845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000096/wk-form4_1758832845.xml","form_type":"4"}},{"id":1032326,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-25T20:40:48.000Z","date":"2025-09-24","kind":"exercise","planned":false,"acquired":false,"shares":1932,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully vested as of June 12, 2024."}],"balance_after":0,"derivative":{"exercise_price":14.36,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":1932},"source":{"system":"sec-edgar","filing":"0001689548-25-000096","document":"wk-form4_1758832845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000096/wk-form4_1758832845.xml","form_type":"4"}},{"id":1032325,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-25T20:40:48.000Z","date":"2025-09-24","kind":"exercise","planned":false,"acquired":true,"shares":1753,"price":44.04,"value":77202.12,"ownership":{"direct":true},"balance_after":17251,"source":{"system":"sec-edgar","filing":"0001689548-25-000096","document":"wk-form4_1758832845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000096/wk-form4_1758832845.xml","form_type":"4"}},{"id":1032324,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-25T20:40:48.000Z","date":"2025-09-24","kind":"exercise","planned":false,"acquired":true,"shares":8566,"price":44.25,"value":379045.5,"ownership":{"direct":true},"balance_after":15498,"source":{"system":"sec-edgar","filing":"0001689548-25-000096","document":"wk-form4_1758832845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000096/wk-form4_1758832845.xml","form_type":"4"}},{"id":1032323,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-25T20:40:48.000Z","date":"2025-09-24","kind":"exercise","planned":false,"acquired":true,"shares":1932,"price":14.36,"value":27743.52,"ownership":{"direct":true},"balance_after":6932,"source":{"system":"sec-edgar","filing":"0001689548-25-000096","document":"wk-form4_1758832845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000096/wk-form4_1758832845.xml","form_type":"4"}},{"id":1100250,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:55:31.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":10520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025."}],"balance_after":10520,"derivative":{"exercise_price":44.04,"expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001689548-25-000081","document":"wk-form4_1751057725.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000081/wk-form4_1751057725.xml","form_type":"4"}},{"id":1138830,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-21T23:15:51.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":24258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":24258,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001415889-25-014015","document":"form4-05212025_110547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588925014015/form4-05212025_110547.xml","form_type":"4"}},{"id":1138829,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-05-21T23:15:51.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":10649,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":91204,"source":{"system":"sec-edgar","filing":"0001415889-25-014015","document":"form4-05212025_110547.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588925014015/form4-05212025_110547.xml","form_type":"4"}},{"id":1488459,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T22:56:15.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":8566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 5, 2024."}],"balance_after":8566,"derivative":{"exercise_price":44.25,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":8566},"source":{"system":"sec-edgar","filing":"0001689548-24-000078","document":"wk-form4_1717714567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000078/wk-form4_1717714567.xml","form_type":"4"}},{"id":1520439,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-10T22:09:04.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":23576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":23576,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001415889-24-012915","document":"form4-05102024_100546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588924012915/form4-05102024_100546.xml","form_type":"4"}},{"id":1520438,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-05-10T22:09:04.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":10537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80555,"source":{"system":"sec-edgar","filing":"0001415889-24-012915","document":"form4-05102024_100546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588924012915/form4-05102024_100546.xml","form_type":"4"}},{"id":1546813,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:38.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":3.48,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-010432","document":"form4-04052024_040425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010432/form4-04052024_040425.xml","form_type":"4"}},{"id":1546812,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:38.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":8.38,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001415889-24-010432","document":"form4-04052024_040425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010432/form4-04052024_040425.xml","form_type":"4"}},{"id":1546811,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:38.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":24.46,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001415889-24-010432","document":"form4-04052024_040425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010432/form4-04052024_040425.xml","form_type":"4"}},{"id":1546810,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:38.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":121503,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":5.63,"expiration_date":"2030-08-18","underlying":"Common Stock","underlying_shares":121503},"source":{"system":"sec-edgar","filing":"0001415889-24-010432","document":"form4-04052024_040425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010432/form4-04052024_040425.xml","form_type":"4"}},{"id":1572221,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock (Right to Buy)","published_at":"2024-03-18T22:14:05.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":101626,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":101626,"derivative":{"exercise_price":1.43,"exercise_date":"2024-03-14","expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":101626},"source":{"system":"sec-edgar","filing":"0000950103-24-003951","document":"dp208510_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324003951/dp208510_4-mitchell.xml","form_type":"4"}},{"id":1572220,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-03-18T22:14:05.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":87412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in full on March 14, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in full on March 14, 2025."}],"balance_after":87412,"derivative":{"underlying":"Common Stock","underlying_shares":87412},"source":{"system":"sec-edgar","filing":"0000950103-24-003951","document":"dp208510_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324003951/dp208510_4-mitchell.xml","form_type":"4"}},{"id":1572219,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-18T22:14:05.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":39510,"price":1.43,"value":56499.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued to the reporting person in lieu of an annual retainer of $56,499."}],"balance_after":503183,"source":{"system":"sec-edgar","filing":"0000950103-24-003951","document":"dp208510_4-mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324003951/dp208510_4-mitchell.xml","form_type":"4"}},{"id":1580861,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-03-12T23:54:43.000Z","date":"2024-03-09","kind":"exercise","planned":false,"acquired":false,"shares":106837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in full on March 9, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in full on March 9, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":106837},"source":{"system":"sec-edgar","filing":"0000950103-24-003747","document":"dp208301_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324003747/dp208301_4-mitchell.xml","form_type":"4"}},{"id":1580860,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-12T23:54:43.000Z","date":"2024-03-09","kind":"exercise","planned":false,"acquired":true,"shares":106837,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen common stock."}],"balance_after":463673,"source":{"system":"sec-edgar","filing":"0000950103-24-003747","document":"dp208301_4-mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324003747/dp208301_4-mitchell.xml","form_type":"4"}},{"id":1650497,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650496,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650495,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.77,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650494,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":11.21,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650493,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":13.07,"expiration_date":"2025-11-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650492,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":10.1,"expiration_date":"2024-11-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650491,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":142667,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":142667},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650490,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1650489,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T16:48:55.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":103000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-014721","document":"tm245865-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014721/tm245865-16_4seq1.xml","form_type":"4"}},{"id":1705913,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T19:00:22.000Z","date":"2023-09-22","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":14.7,"value":147000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Due to clerical error, this amendment to Form 4 is being filed to correct the number of shares beneficially owned following the reported transaction."}],"balance_after":103000,"source":{"system":"sec-edgar","filing":"0001415889-23-016755","document":"form4a-12202023_121207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923016755/form4a-12202023_121207.xml","form_type":"4/A","original_submission_date":"2023-09-26"}},{"id":1773660,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-26T16:08:39.000Z","date":"2023-09-22","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on 11/12/2013 and was exercisable as to 2,500 shares commencing on February 1, 2014, 2,500 shares commencing on May 1, 2014, 2,500 shares commencing on August 1, 2014, and 2,500 shares commencing on November 1, 2014."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2023-11-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-23-013580","document":"form4-09262023_080933.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923013580/form4-09262023_080933.xml","form_type":"4"}},{"id":1773659,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T16:08:39.000Z","date":"2023-09-22","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":14.7,"value":147000.0,"ownership":{"direct":true},"balance_after":152667,"source":{"system":"sec-edgar","filing":"0001415889-23-013580","document":"form4-09262023_080933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923013580/form4-09262023_080933.xml","form_type":"4"}},{"id":1773886,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-25T20:02:13.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.41,"value":35250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.39 to $1.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) this Form 4."}],"balance_after":356836,"source":{"system":"sec-edgar","filing":"0000950103-23-013963","document":"dp200416_4-mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323013963/dp200416_4-mitchell.xml","form_type":"4"}},{"id":1853412,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:46:47.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":19597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":19597,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001415889-23-009949","document":"form4-06162023_080641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009949/form4-06162023_080641.xml","form_type":"4"}},{"id":1853411,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-06-16T16:46:47.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":13090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."}],"balance_after":13090,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001415889-23-009949","document":"form4-06162023_080641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009949/form4-06162023_080641.xml","form_type":"4"}},{"id":1855936,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T11:12:36.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":28981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 12, 2023."}],"balance_after":28981,"derivative":{"exercise_price":0.957,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":28981},"source":{"system":"sec-edgar","filing":"0001689548-23-000106","document":"wf-form4_168674114401080.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000106/wf-form4_168674114401080.xml","form_type":"4"}},{"id":1857312,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-13T18:30:53.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 12, 2023 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":25000,"derivative":{"exercise_price":3.48,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-036865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919123036865/doc4.xml","form_type":"4"}},{"id":1904190,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-04T22:43:06.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":22044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":22044,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001415889-23-007380","document":"form4-05042023_100558.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588923007380/form4-05042023_100558.xml","form_type":"4"}},{"id":1904189,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-04T22:43:06.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":9132,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70018,"source":{"system":"sec-edgar","filing":"0001415889-23-007380","document":"form4-05042023_100558.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588923007380/form4-05042023_100558.xml","form_type":"4"}},{"id":1937916,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T17:11:11.000Z","date":"2023-03-24","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.8363,"value":41815.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8297 to $0.8596, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001104659-23-037022","document":"tm2310645-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000110465923037022/tm2310645-2_4seq1.xml","form_type":"4"}},{"id":1956616,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock (Right to Buy)","published_at":"2023-03-13T21:11:42.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":125489,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125489,"derivative":{"exercise_price":1.17,"exercise_date":"2023-03-09","expiration_date":"2033-03-09","underlying":"Common Stock","underlying_shares":125489},"source":{"system":"sec-edgar","filing":"0000950103-23-004013","document":"dp190529_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323004013/dp190529_4-mitchell.xml","form_type":"4"}},{"id":1956615,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-03-13T21:11:42.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":106837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit ('RSU\") represents a contingent right to receive one share of Precigen common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in full on March 9, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in full on March 9, 2024."}],"balance_after":106837,"derivative":{"underlying":"Common Stock","underlying_shares":106837},"source":{"system":"sec-edgar","filing":"0000950103-23-004013","document":"dp190529_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323004013/dp190529_4-mitchell.xml","form_type":"4"}},{"id":1956614,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-13T21:11:42.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":48290,"price":1.17,"value":56499.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued to the reporting person in lieu of an annual retainer of $56,500."}],"balance_after":331836,"source":{"system":"sec-edgar","filing":"0000950103-23-004013","document":"dp190529_4-mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323004013/dp190529_4-mitchell.xml","form_type":"4"}},{"id":1992807,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-25T01:07:27.000Z","date":"2023-02-22","kind":"exercise","acquired":false,"shares":61576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in full on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in full on February 22, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":61576},"source":{"system":"sec-edgar","filing":"0000950103-23-003027","document":"dp189557_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323003027/dp189557_4-mitchell.xml","form_type":"4"}},{"id":1992806,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-25T01:07:27.000Z","date":"2023-02-22","kind":"exercise","acquired":true,"shares":61576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen common stock."}],"balance_after":283546,"source":{"system":"sec-edgar","filing":"0000950103-23-003027","document":"dp189557_4-mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323003027/dp189557_4-mitchell.xml","form_type":"4"}},{"id":2070647,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2023-01-04T16:21:43.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":3024,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":142667,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3024},"source":{"system":"sec-edgar","filing":"0001415889-23-000303","document":"form4-01042023_090125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923000303/form4-01042023_090125.xml","form_type":"4"}},{"id":2146108,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-10-04T16:05:13.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":3138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":139643,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3138},"source":{"system":"sec-edgar","filing":"0001415889-22-010213","document":"form4-10042022_011057.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922010213/form4-10042022_011057.xml","form_type":"4"}},{"id":2215881,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-07-05T16:49:28.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":136505,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001415889-22-007358","document":"form4-07052022_010738.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922007358/form4-07052022_010738.xml","form_type":"4"}},{"id":2228956,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T16:19:27.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":44000,"price":3.37,"value":148280.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":44000,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001415889-22-006734","document":"form4-06172022_010606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006734/form4-06172022_010606.xml","form_type":"4"}},{"id":2228955,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-06-17T16:19:27.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":133172,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-22-006734","document":"form4-06172022_010606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006734/form4-06172022_010606.xml","form_type":"4"}},{"id":2231542,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-15T17:00:44.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":20250,"derivative":{"exercise_price":8.38,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001209191-22-037022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919122037022/doc4.xml","form_type":"4"}},{"id":2237788,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T23:21:00.000Z","date":"2022-06-08","kind":"purchase","acquired":true,"shares":25000,"price":1.8075,"value":45187.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.795 to $1.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001689548-22-000075","document":"wf-form4_165481684513057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000075/wf-form4_165481684513057.xml","form_type":"4"}},{"id":2253543,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T21:26:37.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":22753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on May 26, 2022."}],"balance_after":22753,"derivative":{"exercise_price":8.38,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":22753},"source":{"system":"sec-edgar","filing":"0001689548-22-000066","document":"wf-form4_165368676658802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000066/wf-form4_165368676658802.xml","form_type":"4"}},{"id":2288652,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2022-04-29T01:04:43.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":28000,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001415889-22-004332","document":"form4-04282022_060430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588922004332/form4-04282022_060430.xml","form_type":"4"}},{"id":2288651,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-04-29T01:04:43.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":9852,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":60886,"source":{"system":"sec-edgar","filing":"0001415889-22-004332","document":"form4-04282022_060430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000141588922004332/form4-04282022_060430.xml","form_type":"4"}},{"id":2309837,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-04-04T16:12:31.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":3151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":118172,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3151},"source":{"system":"sec-edgar","filing":"0001179110-22-002536","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022002536/edgar.xml","form_type":"4"}},{"id":2315213,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-03-29T21:03:02.000Z","date":"2022-03-25","kind":"exercise","acquired":false,"shares":16212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in full on March 25, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in full on March 25, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16212},"source":{"system":"sec-edgar","filing":"0000950103-22-005401","document":"dp170040_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322005401/dp170040_4-mitchell.xml","form_type":"4"}},{"id":2315212,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-29T21:03:02.000Z","date":"2022-03-25","kind":"exercise","acquired":true,"shares":16212,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen common stock."}],"balance_after":221970,"source":{"system":"sec-edgar","filing":"0000950103-22-005401","document":"dp170040_4-mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322005401/dp170040_4-mitchell.xml","form_type":"4"}},{"id":2374451,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock (Right to Buy)","published_at":"2022-02-24T22:49:22.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":83189,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":83189,"derivative":{"exercise_price":2.03,"exercise_date":"2022-02-22","expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":83189},"source":{"system":"sec-edgar","filing":"0000950103-22-003222","document":"dp167774_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322003222/dp167774_4-mitchell.xml","form_type":"4"}},{"id":2374450,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-24T22:49:22.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":61576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit ('RSU\") represents a contingent right to receive one share of Precigen common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in full on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in full on February 22, 2023."}],"balance_after":61576,"derivative":{"underlying":"Common Stock","underlying_shares":61576},"source":{"system":"sec-edgar","filing":"0000950103-22-003222","document":"dp167774_4-mitchell.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322003222/dp167774_4-mitchell.xml","form_type":"4"}},{"id":2374449,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-24T22:49:22.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":27832,"price":2.03,"value":56498.96,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued to the reporting person in lieu of an annual retainer of $56,500."}],"balance_after":205758,"source":{"system":"sec-edgar","filing":"0000950103-22-003222","document":"dp167774_4-mitchell.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322003222/dp167774_4-mitchell.xml","form_type":"4"}},{"id":2452169,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-01-04T16:01:41.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":115021,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1819},"source":{"system":"sec-edgar","filing":"0001179110-22-000099","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022000099/edgar.xml","form_type":"4"}},{"id":2555233,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-10-01T16:11:46.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":2380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":113202,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2380},"source":{"system":"sec-edgar","filing":"0001179110-21-009040","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021009040/edgar.xml","form_type":"4"}},{"id":2580434,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":false,"shares":50000,"price":4.56,"value":228000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 12,500 shares on each of 9/1/20, 12/1/20, 3/1/21, and 6/1/21, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.56,"exercise_date":"2020-09-01","expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2580433,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":false,"shares":18000,"price":2.1,"value":37800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable as to 4,500 shares on each of 9/1/19, 12/1/19, 3/1/20, and 6/1/20, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.1,"exercise_date":"2019-09-01","expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2580432,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":false,"shares":10000,"price":4.64,"value":46400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 2,500 shares on each of 9/1/17, 12/1/17, 3/1/18, and 6/1/18, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.64,"exercise_date":"2017-09-01","expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2580431,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":false,"shares":5000,"price":1.84,"value":9200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable as to 2,500 shares on each of 3/1/17 and 6/1/17, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.84,"exercise_date":"2017-03-01","expiration_date":"2026-12-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2580430,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":true,"shares":50000,"price":4.56,"value":228000.0,"ownership":{"direct":true},"balance_after":93000,"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2580429,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":true,"shares":18000,"price":2.1,"value":37800.0,"ownership":{"direct":true},"balance_after":43000,"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2580428,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":true,"shares":10000,"price":4.64,"value":46400.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2580427,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T16:06:44.000Z","date":"2021-09-03","kind":"exercise","acquired":true,"shares":5000,"price":1.84,"value":9200.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001179110-21-008587","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008587/edgar.xml","form_type":"4"}},{"id":2646305,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-07-02T16:24:34.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":2048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":110822,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2048},"source":{"system":"sec-edgar","filing":"0001179110-21-007320","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021007320/edgar.xml","form_type":"4"}},{"id":2664975,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T16:21:41.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":44000,"price":6.77,"value":297880.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 11,000 shares on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":44000,"derivative":{"exercise_price":6.77,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001179110-21-006813","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021006813/edgar.xml","form_type":"4"}},{"id":2664974,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-06-17T16:21:41.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":108774,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001179110-21-006813","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021006813/edgar.xml","form_type":"4"}},{"id":2670334,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T20:20:23.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 11, 2021 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":20250,"derivative":{"exercise_price":24.46,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001209191-21-040440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919121040440/doc4.xml","form_type":"4"}},{"id":2675734,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-09T21:05:36.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":22343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 8, 2021."}],"balance_after":22343,"derivative":{"exercise_price":20.42,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":22343},"source":{"system":"sec-edgar","filing":"0001689548-21-000062","document":"wf-form4_162327272030058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954821000062/wf-form4_162327272030058.xml","form_type":"4"}},{"id":2735671,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2021-04-29T22:13:33.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-21-004700","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000117911021004700/edgar.xml","form_type":"4"}},{"id":2735670,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-29T22:13:33.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":9828,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51034,"source":{"system":"sec-edgar","filing":"0001179110-21-004700","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1199297/000117911021004700/edgar.xml","form_type":"4"}},{"id":2762674,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-04-02T13:01:22.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":93774,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001179110-21-004071","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021004071/edgar.xml","form_type":"4"}},{"id":2769201,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock (Right to Buy)","published_at":"2021-03-29T23:48:21.000Z","date":"2021-03-25","kind":"grant","acquired":false,"shares":22107,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22107,"derivative":{"exercise_price":7.71,"exercise_date":"2021-03-25","expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":22107},"source":{"system":"sec-edgar","filing":"0001123292-21-000567","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000112329221000567/edgar.xml","form_type":"4"}},{"id":2769200,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-03-29T23:48:21.000Z","date":"2021-03-25","kind":"grant","acquired":false,"shares":16212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Precigen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in full on March 25, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in full on March 25, 2022."}],"balance_after":16212,"derivative":{"underlying":"Common Stock","underlying_shares":16212},"source":{"system":"sec-edgar","filing":"0001123292-21-000567","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000112329221000567/edgar.xml","form_type":"4"}},{"id":2769199,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-29T23:48:21.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":7328,"price":7.71,"value":56498.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued to the reporting person in lieu of an annual retainer of $56,500."}],"balance_after":177926,"source":{"system":"sec-edgar","filing":"0001123292-21-000567","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000112329221000567/edgar.xml","form_type":"4"}},{"id":2785953,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-03-16T20:33:49.000Z","date":"2021-03-13","kind":"exercise","acquired":false,"shares":62189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in full on March 13, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in full on March 13, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":62189},"source":{"system":"sec-edgar","filing":"0001123292-21-000485","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000112329221000485/edgar.xml","form_type":"4"}},{"id":2785952,"issuer":{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN"},"owners":[{"id":17741,"kind":"person","name":"MITCHELL DEAN J","position":1,"cik":"0001199297","reported_name":"MITCHELL DEAN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T20:33:49.000Z","date":"2021-03-13","kind":"exercise","acquired":true,"shares":62189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Precigen, Inc. common stock."}],"balance_after":170598,"source":{"system":"sec-edgar","filing":"0001123292-21-000485","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356090/000112329221000485/edgar.xml","form_type":"4"}}],"next_cursor":"2021-03-16T20:33:49.000000Z,2785952"}